Can-Fite BioPharma Ltd. (NYSE:CANF – Get Free Report) shot up 5.4% during mid-day trading on Wednesday . The stock traded as high as $2.43 and last traded at $2.34. 111,037 shares changed hands during mid-day trading, an increase of 96% from the average session volume of 56,560 shares. The stock had previously closed at $2.22.
Analyst Ratings Changes
CANF has been the subject of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Can-Fite BioPharma in a research note on Thursday, May 9th. EF Hutton Acquisition Co. I raised Can-Fite BioPharma to a “strong-buy” rating in a research report on Wednesday, July 17th. Finally, StockNews.com started coverage on Can-Fite BioPharma in a research report on Friday, July 19th. They issued a “hold” rating on the stock.
View Our Latest Research Report on CANF
Can-Fite BioPharma Stock Down 4.2 %
Institutional Investors Weigh In On Can-Fite BioPharma
A hedge fund recently bought a new stake in Can-Fite BioPharma stock. Armistice Capital LLC bought a new position in Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 154,363 shares of the company’s stock, valued at approximately $340,000. Armistice Capital LLC owned about 4.36% of Can-Fite BioPharma as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 21.00% of the company’s stock.
About Can-Fite BioPharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.
Featured Stories
- Five stocks we like better than Can-Fite BioPharma
- How to Invest in the Best Canadian Stocks
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- How Can Investors Benefit From After-Hours Trading
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.